Table of Contents:
I. Request for Information: Access and use of data from the Adolescent Brain Cognitive Development Study. NOT-DA-21-055 Response needed by June 30, 2021
II. Avenir Award Program for Genetics and Epigenetics of Substance Use Disorders (DP1) PAR-20-225. Next application deadline: October 19, 2021 by 5PM local time of applicant organization.
III. Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) RFA-DA-22-006 (R01). Application due date: October 25, 2021 by 5PM local time of applicant organization.
IV. NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed) PAR-21-244
Next application deadline: July 26, 2021by 5PM local time of applicant organization.
I. Request for Information: Access and use of data from the Adolescent Brain Cognitive Development Study. NOT-DA-21-055 Response needed by June 30, 2021
NIH has issued a Request for Information (RFI) to solicit feedback from the external scientific community about ABCD data access and use. The NIH is publishing this RFI to seek input on topics to inform development of data use guidelines, cloud-based analytic tools, and other resources from its stakeholders, including members of the scientific community, academic institutions, the private sector, health professionals, professional societies, as well as other interested members of the public. Click here to view the RFI. Please submit responses by June 30, 2021 and direct all inquiries to Dr. Elizabeth Hoffman at adolescentbrain@nih.gov.
II. The Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) PAR-20-225.
Next application deadline: October 19, 2021 by 5PM local time of applicant organization.
The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.
If you are interested please read the entire announcement: https://grants.nih.gov/grants/guide/pa-files/PAR-20-225.html If you have questions, please contact:
Jonathan D. Pollock, Ph.D.
301-435-1309
John Satterlee, Ph.D.
301-435-1020
III. Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) RFA-DA-22-006 (R01). Application due date: October 25, 2021 by 5PM local time of applicant organization.
The purpose of this funding opportunity is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic research. This initiative focuses on technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and SUD mechanistic or therapeutic research. The development of combination Anti-retroviral therapy for HIV has transformed HIV/AIDS into a chronic disease by suppressing viral replication to undetectable levels. However, even after combination anti-retroviral therapy, HIV reservoirs remain in the gut, the immune system, and the nervous system where HIV infected CD4+ T cells, macrophages, dendritic cells and microglia may reside. Thus, no cure has been found for HIV infection and no effective vaccine for HIV exists. Current anti-retroviral therapies also have problems with drug toxicity, bioavailability, and have not been formulated for sustained release. Long term sustained delivery is needed among people with substance use disorders where compliance with an anti-retroviral therapy regimen may be problematic. To address these issues the development of improved reagents or technologies to enable targeted delivery of reagents (e.g. small molecules, biologics, gene editing reagents, etc.) to particular CNS regions or cell types is of great interest. Such delivery systems would improve our ability to monitor or manipulate HIV and SUD processes and could serve as the foundation for improved future therapeutics for HIV and/or SUD. Targeted delivery of CRISPr/CAS9 constructs, a gene editing technology, to HIV reservoirs has the potential to eradicate and cure HIV. The effectiveness of gene editing technology may be enhanced through combination with nano-formulations of anti-retroviral therapeutic agents.Such nano-formulations could potentially reduce drug toxicity, improve bioavailability, and provide vehicles for sustained delivery to the periphery and the central nervous system. Sustained delivery formulations that suppress viral expression in the blood stream may eradicate HIV transmission as effectively as a vaccine among drug abusing populations who have problems with treatment compliance.
Applications without proposed technology developments to improve the delivery of cargoes for HIV and SUD research will be considered non-responsive and returned without review.
IV. NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed) PAR-21-244
Next application deadline: July 26, 2021by 5PM local time of applicant organization.
The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level ‘omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L
No comments:
Post a Comment